Bausch Health unit moves to settle charges it misled investors -SEC

WASHINGTON (Reuters) – Salix Pharmaceuticals, a unit of Bausch Health Companies Inc (TO:), has moved to settle charges brought by the U.S. Securities and Exchange Commission that it misled investors about the company’s prospects, the SEC said on Friday.

As part of the proposed settlement, which must be approved by a U.S. district court, Salix agreed to an SEC order to avoid future violations of antifraud and corporate reporting provisions of federal securities laws, the agency said.

A former chief financial officer at Salix, Adam Derbyshire, was also charged and agreed to a settlement in which he will pay more than $1 million, the SEC said. A lawyer for Derbyshire said he had no comment on the settlement.

The alleged misconduct occurred before Salix was acquired by Valeant Pharmaceuticals (NYSE:) International, which is now known as Bausch Health, according to the agency.

In a statement, Salix said it was pleased to reach the settlement, and has “completely transformed” since its acquisition by Bausch in 2015.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.